652 related articles for article (PubMed ID: 26331536)
1. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.
Collins HM; Abdelghany MK; Messmer M; Yue B; Deeves SE; Kindle KB; Mantelingu K; Aslam A; Winkler GS; Kundu TK; Heery DM
BMC Cancer; 2013 Jan; 13():37. PubMed ID: 23356739
[TBL] [Abstract][Full Text] [Related]
3. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.
Vaughan CA; Singh S; Windle B; Sankala HM; Graves PR; Andrew Yeudall W; Deb SP; Deb S
Arch Biochem Biophys; 2012 Feb; 518(1):79-88. PubMed ID: 22198284
[TBL] [Abstract][Full Text] [Related]
5. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes.
Wiersma M; Bussiere M; Halsall JA; Turan N; Slany R; Turner BM; Nightingale KP
Epigenetics Chromatin; 2016; 9():52. PubMed ID: 27895715
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.
Rahnamoun H; Hong J; Sun Z; Lee J; Lu H; Lauberth SM
J Biol Chem; 2018 Aug; 293(34):13234-13246. PubMed ID: 29954944
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
9. Histone acetylation and methylation: combinatorial players for transcriptional regulation.
An W
Subcell Biochem; 2007; 41():351-69. PubMed ID: 17484136
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
12. miR-193a targets MLL1 mRNA and drastically decreases MLL1 protein production: Ectopic expression of the miRNA aberrantly lowers H3K4me3 content of the chromatin and hampers cell proliferation and viability.
Sengupta D; Deb M; Kar S; Parbin S; Pradhan N; Patra SK
Gene; 2019 Jul; 705():22-35. PubMed ID: 31005612
[TBL] [Abstract][Full Text] [Related]
13. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases.
Barlev NA; Liu L; Chehab NH; Mansfield K; Harris KG; Halazonetis TD; Berger SL
Mol Cell; 2001 Dec; 8(6):1243-54. PubMed ID: 11779500
[TBL] [Abstract][Full Text] [Related]
14. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
[TBL] [Abstract][Full Text] [Related]
15. The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
Abraham CG; Espinosa JM
Cancer Cell; 2015 Oct; 28(4):407-408. PubMed ID: 26461087
[TBL] [Abstract][Full Text] [Related]
16. Lysine methylation represses p53 activity in teratocarcinoma cancer cells.
Zhu J; Dou Z; Sammons MA; Levine AJ; Berger SL
Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9822-7. PubMed ID: 27535933
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
18. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.
Weber LM; Jia Y; Stielow B; Gisselbrecht SS; Cao Y; Ren Y; Rohner I; King J; Rothman E; Fischer S; Simon C; Forné I; Nist A; Stiewe T; Bulyk ML; Wang Z; Liefke R
Nucleic Acids Res; 2023 Jan; 51(2):574-594. PubMed ID: 36537216
[TBL] [Abstract][Full Text] [Related]
19. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Fagan RJ; Dingwall AK
Cancer Lett; 2019 Aug; 458():56-65. PubMed ID: 31128216
[TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase MLL1 permits the oscillation of circadian gene expression.
Katada S; Sassone-Corsi P
Nat Struct Mol Biol; 2010 Dec; 17(12):1414-21. PubMed ID: 21113167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
